Mechanisms of involvement of eicosanoids and their precursors in the pathophysiology and treatment of schizophrenia

Medicinal Chemistry

Volumn 9, Issue 6, 2013, Pages 763-773

  Schmidt, Luise ^a   Ceglarek, Uta ^a,b   Kortz, Linda ^a,b   Hoop, Marcus ^c   Kirkby, Kenneth Clifford ^d   Thiery, Joachim ^b   Himmerich, Hubertus ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Antipsychotics; Schizophrenia; Thromboxane A2; Thromboxane B2

Indexed keywords

ARACHIDONIC ACID; CHLORPROMAZINE; CLOZAPINE; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; ESTRADIOL; GAMMA LINOLENIC ACID; HALOPERIDOL; ICOSANOID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; MEPYRAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENTOLAMINE; POLYUNSATURATED FATTY ACID; PROMETHAZINE; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN J2; SULPIRIDE; THROMBOXANE; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANE RECEPTOR; THYROID HORMONE; TOCOPHEROL; TRIFLUOPERAZINE;

ARTICLE; COGNITION; DIFFUSION TENSOR IMAGING; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG MECHANISM; FATIGUE; HUMAN; ICOSANOID METABOLISM; IMMUNE RESPONSE; META ANALYSIS (TOPIC); NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; SCHIZOPHRENIA; SECOND MESSENGER; SIGNAL TRANSDUCTION; SLEEP WAKING CYCLE;

ANTIPSYCHOTIC AGENTS; EICOSANOIDS; HUMANS; SCHIZOPHRENIA;

EID: 84883366931     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406411309060002     Document Type: Article

References (118)

1. Kraepelin, E. Psychiatrie: Ein Lehrbuch f. Studierende u. Aerzte, 1910.
2. Bleuler, E. Dementia praecox oder Gruppe der Schizophrenien; Deuticke: Leipzig, 1911.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR; Washington, DC, 2000.
4. World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems; World Health Organization: Geneva, 1994.
5. Andreasen, N.C.; Olsen, S. Negative v positive schizophrenia. Definition and validation. Arch. Gen. Psychiatry., 1982, 39, 789-94.
6. Lindenmayer, J.P.; Grochowski, S.; Hyman, R.B. Five factor model of schizophrenia: replication across samples. Schizophr. Res., 1995, 14, 229-34.
7. Kay, S.R.; Sevy, S. Pyramidical model of schizophrenia. Schizophr. Bull., 1990, 16, 537-545.
8. Jablensky, A. Subtyping schizophrenia: implications for genetic research. Mol. Psychiatry., 2006, 11, 815-36.
9. Bray, N.J.; Leweke, F.M.; Kapur, S.; Meyer-Lindenberg, A. The neurobiology of schizophrenia: new leads and avenues for treatment. Curr. Opin. Neurobiol., 2010, 20, 810-5.
10. Balu, D.T., Coyle, J.T. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci. Biobehav. Rev., 2011, 35, 848-70.
11. Lwin, A.; Symeon, C.; Jan, F.; Sule. A. Morbidity and mortality in schizophrenia. Br. J. Hosp. Med., 2011, 72, 628-30.
12. Marks, F.; Fürstenberger, G. Prostaglandins, leukotrienes, and other eicosanoids: From biogenesis to clinical application; Wiley-VCH: Weinheim, New York, 1999.
13. Moore, S.A.; Yoder, E.; Spector, A.A. Role of the blood-brain barrier in the formation of long-chain omega-3 and omega-6 fatty acids from essential fatty acid precursors. J. Neurochem., 1990, 55, 391-402.
14. Moore, S.A.; Yoder, E.; Murphy, S.; Dutton, G.R.; Spector, A.A. Astrocytes, not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid (20:4 omega-6). J. Neurochem., 1991, 56, 518-24.
15. Chen, H.; Dzitoyeva, S.; Manev, H. 5-Lipoxygenase in mouse cerebellar Purkinje cells. Neuroscience., 2010, 171, 383-9.
16. Kaufmann, W.E.; Worley, P.F.; Pegg, J.; Bremer, M.; Isakson, P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 2317-21.
17. Coleman, R.A.; Smith, W.L.; Narumiya, S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 1994, 46, 205-29.
18. Mitsumori, T.; Furuyashiki, T.; Momiyama, T.; Nishi, A.; Shuto, T.; Hayakawa, T.; Ushikubi, F.; Kitaoka, S.; Aoki, T.; Inoue, H.; Matsuoka, T.; Narumiya, S. Thromboxane receptor activation enhances striatal dopamine release, leading to suppression of GABAergic transmission and enhanced sugar intake. Eur. J. Neurosci., 2011, 34, 594-604.
19. Wacker, M.J.; Wilhelm, H.L.; Gomez, S.E.; Floor, E.; Orr, J.A. Role of serotonin in thromboxane A2-induced coronary chemoreflex. Am. J. Physiol. Heart Circ. Physiol., 2003, 284, 867-75.
20. Weschenfelder, J.; Sander, C.; Kluge, M.; Kirkby, K.C.; Himmerich, H. The influence of cytokines on wakefulness regulation: clinical relevance, mechanisms and methodological problems. Psychiatr. Danub., 2012, 24, 112-26.
21. van Rossum, J. M. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int. Pharmacodyn. Ther., 1966, 160, 492-4.
22. Horn, A. S.; Snyder, S. H. Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. Proc. Natl. Acad. Sci. U.S.A., 1971, 68, 2325-8.
23. Bürki, H.R.; Eichenberger, E.; Sayers, A.C.; White, T.G. Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal. Pharmakopsychiatr. Neuropsychopharmakol., 1975, 8, 115-21.
24. Lieberman, J.A.; Kane, J.M.; Alvir, J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl.), 1987, 91, 415-33.
25. Davis, K.L.; Kahn, R.S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry, 1991, 148, 1474-86.
26. Pogarell, O.; Koch, W.; Karch, S.; Dehning, S.; Müller, N.; Tatsch, K.; Poepperl, G.; Möller, H.-J. Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry, 2012, 45 (Suppl 1), 36-41.
27. Bauer, M.; Praschak-Rieder, N.; Kasper, S.; Willeit, M. Is dopamine neurotransmission altered in prodromal schizophrenia? A review of the evidence. Curr. Pharm. Des., 2012, 18, 1568-79.
28. Remington, G.; Agid, O.; Foussias, G. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Rev. Neurother., 2011, 11, 589-607.
29. Stauffer, V. L.; Song, G.; Kinon, B. J.; Ascher-Svanum, H.; Chen, L.; Feldman, P.D.; Conley, R.R. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr. Res., 2012, 134, 195-201.
30. Lisman, J.E.; Coyle, J.T.; Green, R.W.; Javitt, D.C.; Benes, F.M.; Heckers, S.; Grace, A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci., 2008, 31, 234-42.
31. Ross, B.M. Phospholipid and eicosanoid signaling disturbances in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids, 2003, 69, 407-12.
32. Moncada, S.; Vane, J.R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol. Rev., 1978, 30, 293-331.
33. Di Pietro, N.C.; Seamans, J.K. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry, 2007, 40 Suppl 1, 27-33.
34. Inagaki, N.; Wada, H. Histamine and prostanoid receptors on glial cells. Glia, 1994, 11, 102-9.
35. Gao, H.; Peng, B.; Welch, W.J., Wilcox, C.S. Central thromboxane receptors: mRNA expression and mediation of pressor responses. Am. J. Physiol., 1997, 272, 1493-1500.
36. Ansar, S.; Larsen, C.; Maddahi, A.; Edvinsson, L. Subarachnoid hemorrhage induces enhanced expression of thromboxane A2 receptors in rat cerebral arteries. Brain Res., 2010, 1316, 163-72.
37. Nishihara, M.; Yokotani, K.; Inoue, S.; Osumi, Y. U-46619, a selective thromboxane A2 mimetic, inhibits the release of endogenous noradrenaline from the rat hippocampus in vitro. Jpn. J. Pharmacol., 2000, 82, 226-31.
38. Praticò, D. The neurobiology of isoprostanes and Alzheimer's disease. Biochim. Biophys. Acta. 2010, 1801, 930-3.
39. Dietrich-Muszalska, A.; Olas, B. Isoprostenes as indicators of oxidative stress in schizophrenia. World J. Biol. Psychiatry, 2009, 10, 27-33.
40. Anfossi, G.; Massucco, P.; Mularoni, E.; Cavalot, F.; Burzacca, S.; Mattiello, L.; Trovati, M. Phenothiazines inhibit collagen-induced thromboxane B2 synthesis and increase forskolin anti-aggregating effects in human platelets. Gen. Pharmacol., 1991, 22, 773-8.
41. Kaiya, H.; Imai, H.; Muramatsu, Y.; Nozaki, M.; Fujimura, H.; Adachi, S.; Namba, M. Platelet aggregation response in schizophrenia and prostaglandin E1. Psychiatry Res., 1983, 9, 309-18.
42. Ishigooka, J.; Shizu, Y.; Wakatabe, H.; Tanaka, K.; Miura, S. Different effects of centrally acting drugs on rabbit platelet aggregation: with special reference to selective inhibitory effects of antipsychotics and antidepressants. Biol. Psychiatry, 1985, 20, 866-73.
43. Himmerich, H.; Schmidt, L.; Becker, S.; Kortz, L.; Schonherr, J.; Mergl, R.; Bauer, K.; Sack, U.; Sheldrick, A. J.; Thiery, J.; Ceglarek, U. Impact of clozapine, N-desmethylclozapine and chlorpromazine on thromboxane production in vitro. Med. Chem., 2012, 8, 1032-8.
44. Steinberg, H.; Himmerich, H. Emil Kraepelin's habilitation and his thesis: A pioneer work for modern systematic reviews, psychoimmunological research and categories of psychiatric diseases. World J. Biol. Psychiatry, 2011, Epub.
45. Himmerich, H.; Kirkby, K.C.; Steinberg, H. From Julius Wagner-Jauregg to biomarkers and immunological therapies. World J. Biol. Psychiatry, 2010, 11, 154-5.
46. Debnath, M.; Cannon, D.M.; Venkatasubramanian, G. Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: Associations and functional implications. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 42, 49-62.
47. Berthold-Losleben, M.; Heitmann, S.; Himmerich, H. Antiinflammatory drugs in psychiatry. Inflamm. Allergy Drug Targets, 2009, 8, 266-76.
48. Brown, A.S.; Hooton, J.; Schaefer, C.A.; Zhang, H.; Petkova, E.; Babulas, V.; Perrin, M.; Gorman, J.M.; Susser, E.S. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry, 2004, 161, 889-95.
49. Himmerich, H.; Berthold-Losleben, M.; Pollmächer, T. The relevance of the TNF-alpha system in psychiatric disorders. Fortschr. Neurol. Psychiatr., 2009, 77, 334-45.
50. Müller, N.; Riedel, M.; Ackenheil, M.; Schwarz, M.J. Cellular and humoral immune system in schizophrenia: a conceptual reevaluation. World J. Biol. Psychiatry, 2000, 1, 173-9.
51. van Kammen, D.P.; McAllister-Sistilli, C.G.; Kelley, M.E. In Current update in psychoimmunology; Wieselmann, Ed.; Springer: Berlin, Heidelberg, New York, 1997, pp. 51-55.
52. Müller, N.; Myint, A.-M.; Schwarz, M.J. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr. Pharm. Des., 2011, 17, 130-136.
53. Müller, N.; Myint, A.-M.; Schwarz, M.J. Immunological treatment options for schizophrenia. Curr. Pharm. Biotechnol., 2012, 13, 1606-13.
54. Himmerich, H.; Sorge, S.; Kirkby, K.C.; Steinberg, H. Schizophrene Störungen. Die Entwicklung immunologischer Krankheitsund Therapiekonzepte. Nervenarzt, 2012, 83, 7-8, 10-2, 14-5.
55. Kaiya, H.; Uematsu, M.; Ofuji, M.; Nishida, A.; Takeuchi, K.; Nozaki, M.; Idaka, E. Elevated plasma prostaglandin E2 levels in schizophrenia. J. Neural Transm., 1989, 77, 39-46.
56. Martínez-Gras, I.; Pérez-Nievas, B.G.; García-Bueno, B.; Madrigal, J.L.; Andrés-Esteban, E.; Rodríguez-Jiménez, R.; Hoenicka, J.; Palomo, T.; Rubio, G.; Leza, J.C. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr. Res., 2011, 128, 15-22.
57. Das, I.; Khan, N.S. Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins Leukot. Essent. Fatty Acids, 1998, 58, 165-8.
58. Stolina, M.; Sharma, S.; Lin, Y.; Dohadwala, M.; Gardner, B.; Luo, J.; Zhu, L.; Kronenberg, M.; Miller, P. W.; Portanova, J.; Lee, J. C.; Dubinett, S. M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol., 2000, 164, 361-70.
59. Erhardt, S.; Blennow, K.; Nordin, C.; Skogh, E.; Lindström, L. H.; Engberg, G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett., 2001, 313, 96-8.
60. Nilsson, L. K.; Linderholm, K. R.; Engberg, G.; Paulson, L.; Blennow, K.; Lindström, L.H.; Nordin, C.; Karanti, A.; Persson, P.; Erhardt, S. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res., 2005, 80, 315-22.
61. Linderholm, K.R.; Skogh, E.; Olsson, S.K.; Dahl, M.-L.; Holtze, M.; Engberg, G.; Samuelsson, M.; Erhardt, S. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull., 2012, 38, 426-32.
62. Wonodi, I.; Stine, O.C.; Sathyasaikumar, K.V.; Roberts, R.C.; Mitchell, B.D.; Hong, L.E.; Kajii, Y.; Thaker, G.K.; Schwarcz, R. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch. Gen. Psychiatry, 2011, 68, 665-74.
63. Pocivavsek, A.; Wu, H.Q.; Potter, M.C.; Elmer, G.I.; Pellicciari, R.; Schwarcz, R. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 2011, 36, 2357-67.
64. Müller, N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr. Opin. Investig. Drugs, 2010, 11, 31-42.
65. Himmerich, H.; Steinberg, H. Hormonelle Krankheits-und Therapiekonzepte in der Psychiatrie. Fortschr. Neurol. Psychiatr., 2011, 79, 384-94.
66. Kulkarni, J.; Hayes, E.; Gavrilidis, E. Hormones and schizophrenia. Curr. Opin. Psychiatry, 2012, 25, 89-95.
67. Santos, N.C.; Costa, P.; Ruano, D.; Macedo, A.; Soares, M.J.; Valente, J.; Pereira, A.T.; Azevedo, M. H.; Palha, J. A. Revisiting thyroid hormones in schizophrenia. J. Thyroid Res., 2012, 2012, 569147.
68. Amateau, S.K.; McCarthy, M.M. Induction of PGE2 by estradiol mediates developmental masculinization of sex behavior. Nat. Neurosci., 2004, 7, 643-50.
69. McCarthy, M.M. How it's made: organisational effects of hormones on the developing brain. J. Neuroendocrinol., 2010, 22, 736-42.
70. Carey, L.C.; Valego, N.K.; Chen, K.; Rose, J.C. Thyroid hormone regulates renocortical COX-2 and PGE2 expression in the late gestation fetal sheep. Reprod. Sci., 2008, 15, 598-603.
71. Choi, S.-Y.; Chang, J.; Jiang, B.; Seol, G.-H.; Min, S.-S.; Han, J.-S.; Shin, H.-S.; Gallagher, M.; Kirkwood, A. Multiple receptors coupled to phospholipase C gate long-term depression in visual cortex. J. Neurosci., 2005, 25, 11433-43.
72. Fredriksson, R.; Lagerström, M.C.; Lundin, L.-G.; Schiöth, H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol., 2003, 63, 1256-72.
73. Ohuoha, D.C.; Hyde, T.M.; Kleinman, J.E. The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology (Berl.), 1993, 112 (Suppl 1), 5-15.
74. Goff, D.C.; Coyle, J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry, 2001, 158, 1367-77.
75. Roberts-Crowley, M.L.; Mitra-Ganguli, T.; Liu, L.; Rittenhouse, A.R. Regulation of voltage-gated Ca2+ channels by lipids. Cell Calcium, 2009, 45, 589-601.
76. Horrobin, D.F.; Glen, A.I.; Vaddadi, K. The membrane hypothesis of schizophrenia. Schizophr. Res., 1994, 13, 195-207.
77. Horrobin, D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res., 1998, 30, 193-208.
78. Yao, J.K.; Leonard, S.; Reddy, R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res., 2000, 42, 7-17.
79. Landén, M.; Davidsson, P.; Gottfries, C.-G.; Månsson, J.-E.; Blennow, K. Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia. Schizophr. Res., 2002, 55, 83-8.
80. McNamara, R.K.; Jandacek, R.; Rider, T.; Tso, P.; Hahn, C.-G.; Richtand, N.M.; Stanford, K.E. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr. Res., 2007, 91, 37-50.
81. Freeman, M.P.; Hibbeln, J.R.; Wisner, K.L.; Davis, J.M.; Mischoulon, D.; Peet, M.; Keck, P.E.; Marangell, L.B.; Richardson, A.J.; Lake, J.; Stoll, A.L. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry, 2006, 67, 1954-67.
82. Di, X.; Chan, R. C.K.; Gong, Q.-Y. White matter reduction in patients with schizophrenia as revealed by voxel-based morphometry: an activation likelihood estimation meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33, 1390-4.
83. Connor, C.M.; Crawford, B.C.; Akbarian, S. White matter neuron alterations in schizophrenia and related disorders. Int. J. Dev. Neurosci., 2011, 29, 325-34.
84. Peters, B.D.; Duran, M.; Vlieger, E.J.; Majoie, C.B.; den Heeten, G. J.; Linszen, D.H.; Haan, L. de. Polyunsaturated fatty acids and brain white matter anisotropy in recent-onset schizophrenia: a preliminary study. Prostaglandins Leukot. Essent. Fatty Acids, 2009, 81, 61-3.
85. Peters, B.D.; Machielsen, M.W. J.; Hoen, W.P.; Caan, M.W.A.; Malhotra, A.K.; Szeszko, P. R.; Duran, M.; Olabarriaga, S. D.; Haan, L. de. Polyunsaturated Fatty Acid Concentration Predicts Myelin Integrity in Early-Phase Psychosis. Schizophr. Bull., 2013, Epub.
86. Berger, G.E.; Smesny, S.; Amminger, G.P. Bioactive lipids in schizophrenia. Int. Rev. Psychiatry, 2006, 18, 85-98.
87. Amminger, G.P.; Schäfer, M.R.; Papageorgiou, K.; Klier, C.M.; Cotton, S.M.; Harrigan, S.M.; Mackinnon, A.; McGorry, P.D.; Berger, G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry, 2010, 67, 146-54.
88. Zimmer, L.; Hembert, S.; Durand, G.; Breton, P.; Guilloteau, D.; Besnard, J.C.; Chalon, S. Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci. Lett., 1998, 240, 177-81.
89. Zimmer, L.; Vancassel, S.; Cantagrel, S.; Breton, P.; Delamanche, S.; Guilloteau, D.; Durand, G.; Chalon, S. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am. J. Clin. Nutr., 2002, 75, 662-7.
90. Kordi-Tamandani, D.M.; Sahranavard, R.; Torkamanzehi, A. DNA methylation and expression profiles of the brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) genes in patients with schizophrenia. Mol. Biol. Rep., 2012, 39, 10889-93.
91. Martinotti, G.; Di Iorio, G.; Marini, S.; Ricci, V.; Berardis, D. de; Di Giannantonio, M. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. J. Biol. Regul. Homeost. Agents, 2012, 26, 347-56.
92. Autry, A.E.; Monteggia, L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev., 2012, 64, 238-58.
93. Wu, A.; Ying, Z.; Gomez-Pinilla, F. The interplay between oxidative stress and brain-derived neurotrophic factor modulates the outcome of a saturated fat diet on synaptic plasticity and cognition. Eur. J. Neurosci., 2004, 19, 1699-707.
94. Wu, A.; Ying, Z.; Gomez-Pinilla, F. Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience, 2008, 155, 751-9.
95. Sethom, M.M.; Fares, S.; Bouaziz, N.; Melki, W.; Jemaa, R.; Feki, M.; Hechmi, Z.; Kaabachi, N. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids, 2010, 83, 131-6.
96. Fusar-Poli, P.; Berger, G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J. Clin. Psychopharmacol., 2012, 32, 179-85.
97. Müller, N.; Riedel, M.; Scheppach, C.; Brandstätter, B.; Sokullu, S.; Krampe, K.; Ulmschneider, M.; Engel, R.R.; Möller, H.J.; Schwarz, M.J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry, 2002, 159, 1029-34.
98. Müller, N.; Schwarz, M.J. Immune system and schizophrenia. Curr. Immunol. Rev., 2010, 6, 213-20.
99. Müller, N.; Krause, D.; Dehning, S.; Musil, R.; Schennach-Wolff, R.; Obermeier, M.; Möller, H.J.; Klauss, V.; Schwarz, M.J.; Riedel, M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res., 2010, 121, 118-24.
100. Leung, E.; Walsh, L.K.; Pulido-Rios, M.T.; Eglen, R. M. Characterization of putative 5-ht7 receptors mediating direct relaxation in Cynomolgus monkey isolated jugular vein. Br. J. Pharmacol., 1996, 117, 926-30.
101. Pollmächer, T.; Haack, M.; Schuld, A.; Kraus, T.; Hinze-Selch, D. Effects of antipsychotic drugs on cytokine networks. J. Psychiatr. Res., 2000, 34, 369-82.
102. Ricciotti, E.; Fitz Gerald, G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol., 2011, 31, 986-1000.
103. Rogerio, A.P.; Anibal, F.F. Role of leukotrienes on protozoan and helminth infections. Mediators Inflamm. 2012, 2012, 595694.
104. Berger, G.E.; Proffitt, T.M.; McConchie, M.; Yuen, H.; Wood, S.J.; Amminger, G.P.; Brewer, W.; McGorry, P.D. Ethyleicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J. Clin. Psychiatry, 2007, 68, 1867-75.
105. Emsley, R.; Myburgh, C.; Oosthuizen, P.; van Rensburg, S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry, 2002, 159, 1596-8.
106. Emsley, R.; Niehaus, D.J.; Koen, L.; Oosthuizen, P.P.; Turner, H.J.; Carey, P.; van Rensburg, S.J.; Maritz, J.S.; Murck, H. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebocontrolled trial. Schizophr. Res., 2006, 84, 112-20.
107. Fenton, W.S.; Dickerson, F.; Boronow, J.; Hibbeln, J.R.; Knable, M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry, 2001, 158, 2071-4.
108. Peet, M.; Brind, J.; Ramchand, C.N.; Shah, S.; Vankar, G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res., 2001, 49, 243-51.
109. Peet, M.; Horrobin, D.F.; E-E Multicentre Study Group. A doseranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res., 2002, 36, 7-18.
110. Wolkin, A.; Jordan, B.; Peselow, E.; Rubinstein, M.; Rotrosen, J. Essential fatty acid supplementation in tardive dyskinesia. Am. J. Psychiatry, 1986, 143, 912-4.
111. Kim, H.; Bang, J.; Chang, H.W.; Kim, J.Y.; Park, K.U.; Kim. S.H.; Lee, K.J.; Cho, C.H., Hwang, I.; Park, S.D.; Ha, E.; Jung, S.W. Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. Eur. J. Pharmacol., 2012, 678, 55-60.
112. Cheon Y, Park JY, Modi HR, Kim HW, Lee HJ, Chang L, Rao JS, Rapoport SI. Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E2 concentration in rat brain. J. Neurochem., 2011, 119, 364-76.
113. Adkins, D.E.; Khachane, A.N.; McClay, J.L.; Aberg, K.; Bukszár, J.; Sullivan, P.F.; van den Oord, E.J. SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: data from the CATIE study. Schizophr. Res., 2012, 135, 200-1.
114. Marin, C.; Saldaña, M.; Roca-Ferrer, J.; Bonastre, M.; Aguilar, E.; Mullol, J. Striatal and nigral COX-2 expression after chronic typical and atypical neuroleptic administration in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 678-82.
115. Rappard, F.; Müller, N. Celecoxib Add-on Therapy Does Not Have Beneficial Antipsychotic Effects Over Risperidone Alone in Schizophrenia. Neuropsychopharmacology, 2004, 29 (Suppl. 1), 222.
116. Rapaport, M.H.; Delrahim, K.K.; Bresee, C.J.; Maddux, R.E.; Ahmadpour, O.; Dolnak, D.; Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry, 2005, 57, 1594-6.
117. Zhang, Y.; Chun Chen, D.; Long Tan, Y.; Zhou, D.F. A doubleblind, placebo-controlled trial of celecoxib addes to risperidone in first-episode and drug-naive patients with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2006, 256 (Suppl. 2), II/50.
118. Akhondzadeh, S.; Tabatabaee, M.; Amini, H.; Ahmadi Abhari, S.A.; Abbasi, S.H.; Behnam, B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res., 2007, 90, 179-85.